Methylation regulates HEY1 expression in glioblastoma

Area of Science:

• Neuro-oncology
• Molecular Biology
• Epigenetics

Background:

• Glioblastoma (GBM) is a fatal brain cancer with limited treatment options.
• Identifying novel molecular targets is crucial for improving GBM patient prognosis.
• HEY1, a Notch signaling mediator, is implicated in GBM pathogenesis.

Purpose of the Study:

• To investigate the role of HEY1 methylation in GBM.
• To explore HEY1 as a potential therapeutic target for GBM.

Main Methods:

• Bioinformatic analysis, immunohistochemistry, and immunoblotting to assess HEY1 expression in GBM specimens.
• Bisulfite sequencing to analyze HEY1 promoter methylation.
• Sodium butyrate (NaB) treatment of GBM cell lines to evaluate effects on HEY1 expression and apoptosis.
• Gene silencing of HEY1 to assess its impact on GBM cell invasion, migration, and proliferation.
• Analysis of the regulatory relationship between HEY1 and p53 using immunoblotting and quantitative PCR (q-PCR).

Main Results:

• HEY1 is highly expressed in GBM patient samples.
• The HEY1 promoter is hypermethylated in normal brain tissue compared to GBM.
• NaB treatment reduced HEY1 expression, increased DNMT1, and induced GBM cell apoptosis.
• Silencing HEY1 inhibited GBM cell invasion, migration, and proliferation.
• A positive regulatory loop between HEY1 and p53 was identified.

Conclusions:

• HEY1 methylation status is linked to GBM pathogenesis.
• HEY1 plays a significant role in GBM cell proliferation, migration, and invasion.
• HEY1 represents a potential predictive marker and therapeutic target for glioblastoma.